Institute for Tuberculosis Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China 610041.
Laboratory Medicine, Liangshan Yi Autonomous Prefecture Center for Disease Control and Prevention, Liangshan, Sichuan, China 615000.
J Immunol Res. 2023 Jan 23;2023:4431209. doi: 10.1155/2023/4431209. eCollection 2023.
This study investigated drug-resistant tuberculosis (DR-TB) in the Yi ethnic group. The study was designed to identify risk factors for DR-TB and its relationship with HIV/AIDS. To establish the resistance to antituberculosis drugs, whole-genome sequencing (WGS) was performed using culture-positive samples collected from people of the Yi ethnic group from March 2019 to March 2021. Baseline characteristics were obtained from China's tuberculosis surveillance system. A total of 116 strains were included in the final analysis. Lineage 2.2 (75.86%) was the dominant sublineage, followed by lineage 4.5 (18.97%) and lineage 4.4 (5.17%). The rates of rifampicin-resistant (RR-TB), multidrug-resistant (MDR-TB), and preextensively drug-resistant TB (pre-XDR-TB) were 18.97%, 10.34%, and 6.03%, respectively. Drug-resistant strains were not found in the elderly (age ≥ 65 years). The proportions of RR/MDR-TB and pre-XDR-TB cases among re-treatment patients were higher than those among new patients ( = 12.155, = 0.003; = 22.495, = 0.001, respectively). The pre-XDR-TB case proportions were higher among female patients than among males and higher among referred patients ( = 5.456, = 0.032; = 15.134, = 0.002, respectively). The rates of RR/MDR-TB and pre-XDR-TB did not differ appreciably among groups with different HIV infection statuses nor lineage populations. DR-TB poses a serious challenge to the Yi ethnic group. Re-treatment patients, women, and referred patients were at high risk of MDR/RR-TB or pre-XDR-TB while HIV and lineage 2 had negligible association with drug resistance. Whole-genome sequencing should be used to guide the design of treatment regimens and to tailor public interventions.
本研究调查了彝族人群中的耐药结核病(DR-TB)。该研究旨在确定 DR-TB 的危险因素及其与 HIV/AIDS 的关系。为了确定抗结核药物的耐药性,使用培养阳性样本对 2019 年 3 月至 2021 年 3 月来自彝族人群的患者进行了全基因组测序(WGS)。基线特征来自中国的结核病监测系统。共有 116 株菌株最终纳入分析。优势亚谱系为 2.2 谱系(75.86%),其次是 4.5 谱系(18.97%)和 4.4 谱系(5.17%)。利福平耐药(RR-TB)、耐多药(MDR-TB)和预广泛耐药结核病(pre-XDR-TB)的发生率分别为 18.97%、10.34%和 6.03%。在老年人(年龄≥65 岁)中未发现耐药菌株。复治患者中 RR/MDR-TB 和 pre-XDR-TB 病例的比例高于新患者( = 12.155, = 0.003; = 22.495, = 0.001)。女性患者的 pre-XDR-TB 病例比例高于男性患者,转诊患者的比例高于非转诊患者( = 5.456, = 0.032; = 15.134, = 0.002)。不同 HIV 感染状态和谱系人群之间的 RR/MDR-TB 和 pre-XDR-TB 发生率没有显著差异。DR-TB 对彝族人群构成严重威胁。复治患者、女性和转诊患者患 MDR/RR-TB 或 pre-XDR-TB 的风险较高,而 HIV 和 2 谱系与耐药性的关联性可以忽略不计。全基因组测序应用于指导治疗方案的设计和调整公共干预措施。